We tested 20 different markers that had been reported by others to be able to distinguish poor survival ACC tumors, but only three, MYB, PTK2 (Fak) and SNAI2 (Slug), showed significant differences in our cohort (Table 3). This evidence concerns the gene MYB and adrenal cortex carcinoma.